Evidence map›Paper›PMID 40812667›Full record

ArticleJournal of hepatology2026

Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.

Tim Meyer, Richard S Finn, Mitesh Borad, Amit Mahipal, Julien Edeline, Roch Houot, Petr F Hausner, Antoine Hollebecque, Lipika Goyal, Matthew Frigault and 24 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03132792 (A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03132792 phase1completednot on this map

A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types

TypeinterventionalSponsorAdaptimmuneRan2017 to 2025Enrolled39ConditionsHepatocellular Cancer, AFP Expressing TumorsArmsAutologous genetically modified AFPᶜ³³²T cells
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors.

Tim MeyerUniversity College London, London, UK.
Richard S FinnJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
Mitesh BoradMayo Clinic, Phoenix, AZ, USA.
Amit MahipalMayo Clinic, Rochester, MN, USA; University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
Julien EdelineCentre Eugène-Marquis, Rennes, France.
Roch HouotDepartment of Hematology, University Hospital of Rennes, University of Rennes, Rennes, France.
Petr F HausnerUniversity of Maryland, Baltimore, MD, USA.
Antoine HollebecqueInstitut de Cancérologie Institut Gustave Roussy, Villejuif, France.
Lipika GoyalMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Matthew FrigaultMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Thomas R Jeffry EvansUniversity of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.
Kit Man WongUniversity of Washington/Seattle Cancer Care Alliance, Seattle, WA, USA.
Benjamin R TanWashington University School of Medicine, St. Louis, MO, USA.
Emmanuel MitryPaoli-Calmettes Institute, Marseille, France.
Debashis SarkerKing's College London, London, UK.
Lynn FeunSylvester Comprehensive Cancer Center, Miami, FL, USA.
Bassel El-RayesEmory University School of Medicine, Atlanta, GA, USA.
Fiona ThistlethwaiteThe Christie NHS Foundation Trust and University of Manchester, Manchester, UK.
Ahmed KasebThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Olatunji AleseEmory University School of Medicine, Atlanta, GA, USA.
Zhaohui JinMayo Clinic, Rochester, MN, USA.
Chris CirilloAdaptimmune, Philadelphia, PA, USA.
Jordi BruixBCLC Group, Network for Biomedical Research Center for Hepatic and Digestive Diseases (CIBEREHD), Hospital Clinic, IDIBAPS, Barcelona, Spain.
Claire RoddieUniversity College London, London, UK.
Paul NotoAdaptimmune, Philadelphia, PA, USA.
Svetlana FayngertsAdaptimmune, Philadelphia, PA, USA.
Sebastiano CristianiAdaptimmune, Abingdon, Oxfordshire, UK.
Jennifer SampsonAdaptimmune, Abingdon, Oxfordshire, UK.
Jane BaiAdaptimmune, Philadelphia, PA, USA.
Martin IsabelleAdaptimmune, Abingdon, Oxfordshire, UK.
Robyn BroadAdaptimmune, Abingdon, Oxfordshire, UK.
Amy SunAdaptimmune, Philadelphia, PA, USA.
Elliot NorryAdaptimmune, Philadelphia, PA, USA. Electronic address: ecnorry@gmail.com.
Bruno SangroClinica Universidad de Navarra and CIBEREHD, Pamplona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsPatients with advanced hepatocellular carcinoma (HCC) generally experience poor outcomes despite current therapies, necessitating the development of alternative treatments. ADP-A2AFP is an investigational autologous T-cell therapy with an affinity-enhanced T-cell receptor (TCR) targeting alpha-fetoprotein (AFP).

methodsWe describe a phase I, open-label, first-in-human clinical trial of ADP-A2AFP (NCT03132792) in human leukocyte antigen-eligible participants with AFP-expressing HCC (or other tumor) not amenable to transplant/resection who progressed on, were intolerant to, or refused prior systemic therapy. Participants received lymphodepletion chemotherapy (cyclophosphamide 500 mg/m

resultsTwenty-one participants, 20 with advanced HCC and one with gastric hepatoid carcinoma received ≥1 ADP-A2AFP infusion. All participants experienced ≥1 grade 3 or higher adverse event; 52.4% experienced ≥1 grade 3 or higher event considered related to ADP-A2AFP treatment. Six participants experienced cytokine release syndrome (grade 1-2: n = 5; grade 4: n = 1). Best overall responses were complete response (n = 1), partial response (n = 1), and stable disease (n = 12); overall response rate was 9.5%. Eight patients had a stable disease duration of ≥16 weeks. Infiltration of ADP-A2AFP TCR and CD8+ T cells was seen in AFP-positive areas of post-treatment tumor samples. A relationship was demonstrated between increased ADP-A2AFP dose and serum AFP reduction in responders.

conclusionsLymphodepletion chemotherapy followed by ADP-A2AFP TCR T-cell therapy showed a manageable safety profile and preliminary indications of antitumor activity in these previously treated patients. IMPACT AND IMPLICATIONS: Adoptive T-cell therapy could be a much-needed additional treatment strategy for advanced hepatocellular carcinoma. Clinicians and researchers interested in the development of adoptive T-cell therapies for advanced solid tumors will be interested to learn that in this phase I trial, ADP-A2AFP T-cell receptor T-cell therapy was associated with an acceptable benefit-to-risk profile and encouraging antitumor activity, illustrating the treatment potential of adoptive T-cell therapy for advanced hepatocellular carcinoma. CLINICALTRIALS: GOV NUMBER: NCT03132792; first posted 2017-04-08.

Indexed as

Carcinoma, HepatocellularImmunotherapy, AdoptiveLiver NeoplasmsReceptors, Antigen, T-CellStomach NeoplasmsAdultAgedalpha-FetoproteinsFemaleHumansMaleMiddle AgedT-LymphocytesTreatment OutcomeVidarabinealpha-FetoproteinsReceptors, Antigen, T-CellVidarabineAdoptive T-cell therapyalpha-fetoproteinhepatocellular carcinomaimmunotherapyT-cell receptor T-cell therapy

Identifiers

PMID40812667

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.